Serina Therapeutics, Inc. (SER)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 16
- Market Cap
- $31M
About Serina Therapeutics, Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
SentiSense also tracks daily options readings for Serina Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Serina Therapeutics, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.